Moomoo AI 已提取核心訊息
Cingulate Inc., a company listed in the United States, has received communication from the Securities and Exchange Commission (SEC) regarding its recently filed Registration Statement on Form S-1. The SEC, in a letter dated January 18, 2024, informed Cingulate's CEO Shane Schaffer that it has not reviewed and will not review the company's registration statement, which was filed on January 12, 2024. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures. The SEC's Division of Corporation Finance, Office of Life Sciences, directed any further questions to Daniel Crawford and provided his contact information.
Cingulate Inc., a company listed in the United States, has received communication from the Securities and Exchange Commission (SEC) regarding its recently filed Registration Statement on Form S-1. The SEC, in a letter dated January 18, 2024, informed Cingulate's CEO Shane Schaffer that it has not reviewed and will not review the company's registration statement, which was filed on January 12, 2024. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures. The SEC's Division of Corporation Finance, Office of Life Sciences, directed any further questions to Daniel Crawford and provided his contact information.
在美國上市的公司Cingulate Inc. 已收到美國證券交易委員會（SEC）關於其最近提交的S-1表格註冊聲明的來文。美國證券交易委員會在2024年1月18日的一封信中通知Cingulate首席執行官謝恩·沙弗，它尚未審查也不會審查該公司於2024年1月12日提交的註冊聲明。美國證券交易委員會的信中還提到了與加快註冊程序的請求有關的第460和461條。此外，美國證券交易委員會提醒該公司及其管理層，他們有責任確保披露的準確性和充分性。美國證券交易委員會生命科學辦公室公司財務處向丹尼爾·克勞福德提出了任何進一步的問題，並提供了他的聯繫信息。
在美國上市的公司Cingulate Inc. 已收到美國證券交易委員會（SEC）關於其最近提交的S-1表格註冊聲明的來文。美國證券交易委員會在2024年1月18日的一封信中通知Cingulate首席執行官謝恩·沙弗，它尚未審查也不會審查該公司於2024年1月12日提交的註冊聲明。美國證券交易委員會的信中還提到了與加快註冊程序的請求有關的第460和461條。此外，美國證券交易委員會提醒該公司及其管理層，他們有責任確保披露的準確性和充分性。美國證券交易委員會生命科學辦公室公司財務處向丹尼爾·克勞福德提出了任何進一步的問題，並提供了他的聯繫信息。
有用
沒用